title: [Definitive chemoradiotherapy for esophageal cancer: 66Gy versus 50Gy, a retrospective study].
abstract: OBJECTIVE
  To compare the influence of radiation dose, high dose versus standard dose, on survival for patients with esophageal carcinomas treated with definitive radiochemotherapy.
  
  
  METHODS
  Between 2003 and 2006, 143 consecutive patients with squamous-cell carcinoma and adenocarcinoma, clinical stage I to IVA, treated in two different institutions were retrospectively reviewed, 83 patients had received more than 50.4Gy, median dose 66Gy (50.7-72Gy) and 60 less than or equal to 50.4Gy, median dose 50Gy (38-50.4Gy).
  
  
  RESULTS
  Median age was higher in high dose group (67.6 versus 61.7 years). Nutritional status and stage were better in high dose group with a lower weight loss (5.1 versus 7.9%), a higher body mass index (25.7 versus 22.9), more N0 patients (60.2 versus 31.7%) and less stage III (27.7 versus 63.3%). Median follow up was 20.8 months (2.8-92.4 months), and 64.9 months (4.2-92.4 months) for the 33 surviving patients. No statistically significant difference was shown for local/locoregional control, disease-free survival. Overall survival at 2-, 3- and 5-year and median survival was respectively 44.7%, 36.8%, 19.1% and 21.2 months in high dose group and 50.8%, 31.6%, 20.7% and 24.6 months in standard dose group (P=0.9).
  
  
  CONCLUSIONS
  No difference was found between the two groups in terms of local/distant control and overall survival. A prospective randomised study is needed.
authors.affiliation: Département de radiothérapie, centre de lutte contre le cancer Paul-Strauss, 3, rue de la Porte-de-l'Hôpital, BP 42, 67065 Strasbourg cedex, France.
authors.forename: J-B
authors.initials: JB
authors.lastname: Clavier
authors.forename: D
authors.initials: D
authors.lastname: Antoni
authors.forename: D
authors.initials: D
authors.lastname: Atlani
authors.forename: M
authors.initials: M
authors.lastname: Ben Abdelghani
authors.forename: C
authors.initials: C
authors.lastname: Schumacher
authors.forename: P
authors.initials: P
authors.lastname: Salze
authors.forename: G
authors.initials: G
authors.lastname: Noël
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality / Q000473:pathology / Q000628:therapy; D000328:Adult; D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D015992:Body Mass Index; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000473:pathology / Q000628:therapy; D059248:Chemoradiotherapy; D003680:Deglutition Disorders / Q000209:etiology / Q000628:therapy; D004938:Esophageal Neoplasms / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D009752:Nutritional Status; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D015431:Weight Loss